

12 July 2011 EMA/HMPC/96911/2010 Committee on Herbal Medicinal Products (HMPC)

# Community herbal monograph on *Commiphora molmol* Engler, gummi-resina

Final

Discussion in Working Party on Community monographs and Community	July 2010	
list (MLWP)	September 2010	
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	Contonal au 2010	
for consultation	September 2010	
End of consultation (deadline for comments). Comments should be	15 Mauch 2011	
provided using this template to hmpc.secretariat@ema.europa.eu	15 March 2011	
Rediscussion in Working Party on Community monographs and	M 2011	
Community list (MLWP)	May 2011	
Adoption by Committee on Herbal Medicinal Products (HMPC)	12 July 2011	

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Commiphora molmol Engler, gummi-resina; Myrrha; myrrh

BG (bălgarski): Мира	LT (lietuvių kalba): Mirra
CS (čeština): Myrhovníková klejopryskyřiceDA	LV (latviešu valoda): Mirra
(dansk): Myrra	MT (malti): Mirra
DE (Deutsch): Myrrhe	NL (nederlands): Mirre
EL (elliniká): Σμύρνα (ελλειπές)	PL (polski): Mirra
EN (English): Myrrh	PT (português): Mirra
ES (espanol): Mirra	RO (română): Mir
ET (eesti keel): Mürripuuvaik	SK (slovenčina): Myrha
FI (suomi):	SL (slovenščina): Mira
FR (français): Myrrhe	SV (svenska): Myrra
HU (magyar): Mirha	IS (íslenska):
IT (italiano): Mirra	NO (norsk): Myrra



# Community herbal monograph on *Commiphora molmol* Engler, gummi-resina

## 1. Name of the medicinal product

To be specified for the individual finished product.

## 2. Qualitative and quantitative composition<sup>1, 2</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Commiphora molmol Engler, gummi-resina (myrrh)
	i) Herbal substance Not applicable
	ii) Herbal preparations  Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 90 %  V/V)

#### 3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparation in liquid dosage forms for oromucosal or cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

## 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product for treatment of minor ulcers and inflammation in the mouth

<sup>1</sup> The material complies with the Ph. Eur. monograph (ref.: 01/2008:1349 corrected 6.0).

Community herbal monograph on Commiphora molmol Engler, gummi-resina

EMA/HMPC/96911/2010 Page 2/6

<sup>2</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

(stomatitis and gingivitis).
Indication 2)
Traditional herbal medicinal product for treatment of minor wounds and small boils (furuncles).
The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

## 4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	<u>Oromucosal use</u>
	Indication 1)
	Adolescents, adults and elderly
	i) 0.5-5 ml of tincture in 150 ml of water for rinsing or gargling 3 times daily.
	or
	ii) The undiluted tincture is applied to the affected areas with a cotton bud 2-3 times daily.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	<u>Cutaneous use</u>
	Indication 2)
	Adolescents, adults and elderly
	The wound or furuncle is dabbed 2-3 times daily with undiluted (preferably) or diluted tincture in water.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	If the symptoms persist after 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oromucosal and cutaneous use.

EMA/HMPC/96911/2010 Page 3/6

#### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance.

## 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indications 1) and 2)
	The use in children under 12 years of age is not recommended due to lack of adequate data.
	If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	The appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.
	Indication 2)
	If fever or signs of exacerbating skin infection are observed, a doctor or a qualified health care practitioner should be consulted.
	Small boils (furuncles) in the face should be treated by a medical doctor.
	Eye contact with myrrh tincture should be avoided.

# 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

## 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not
	been established. In the absence of sufficient
	data, the use during pregnancy and lactation is
	not recommended.
	No fertility data available.

EMA/HMPC/96911/2010 Page 4/6

## 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	Allergic skin reactions have been reported. The frequency is not known.
	The tincture contains alcohol, which may cause a transient pain and irritation on application to the mucosa or skin.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

## 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

## 5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.

Page 5/6

EMA/HMPC/96911/2010

Adequate tests on genotoxicity have not been performed.
Tests on reproductive toxicity and carcinogenic potential have not been performed.

# 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

# 7. Date of compilation/last revision

12 July 2011

EMA/HMPC/96911/2010 Page 6/6